Detalles de la búsqueda
1.
Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer.
Cancer Immunol Immunother
; 72(6): 1699-1707, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36617602
2.
Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer.
Oncologist
; 24(8): 1033-e617, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31040252
3.
A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer.
Oncologist
; 24(4): 459-e131, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30578309
4.
Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial.
Oncologist
; 24(5): 593-e170, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30651400
5.
Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer.
Invest New Drugs
; 37(2): 291-296, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30121935
6.
Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial.
Invest New Drugs
; 36(5): 903-910, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29846848
7.
The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations.
BMC Cancer
; 18(1): 1241, 2018 Dec 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30537950
8.
Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients.
Target Oncol
; 19(3): 411-421, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38467958
9.
Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study.
Front Oncol
; 14: 1303543, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38344209
10.
Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50.
Front Immunol
; 15: 1348034, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38464519
11.
Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study.
J Cancer Res Clin Oncol
; 149(6): 2475-2482, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35737092
12.
Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non-small cell lung cancer patients with EGFR mutation: A multicenter retrospective study.
Thorac Cancer
; 14(11): 1004-1011, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36866788
13.
Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum-Etoposide Chemotherapy.
Drugs Aging
; 40(6): 563-571, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37145245
14.
Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study.
JTO Clin Res Rep
; 4(4): 100493, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37025120
15.
Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study.
Target Oncol
; 18(5): 657-665, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37610516
16.
Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer: A multicenter, Phase II trial.
Cancer Med
; 12(14): 15117-15127, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37269194
17.
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
JAMA Netw Open
; 6(7): e2322915, 2023 07 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37432682
18.
First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study.
Cancers (Basel)
; 15(20)2023 Oct 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37894357
19.
Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status.
Target Oncol
; 18(6): 915-925, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37902896
20.
Procaterol-stimulated increases in ciliary bend amplitude and ciliary beat frequency in mouse bronchioles.
Cell Physiol Biochem
; 29(3-4): 511-22, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22508058